1. Vaz-Drago, R., Custódio, N., and Carmo-Fonseca, M. (2017). Deep intronic mutations and human disease. Hum. Genet. 136, 1093–1111.
2. Okubo, M., Noguchi, S., Awaya, T., Hosokawa, M., Tsukui, N., Ogawa, M., Hayashi,
S., Komaki, H., Mori-Yoshimura, M., Oya, Y., et al. (2023). RNA-seq analysis, targeted long-read sequencing and in silico prediction to unravel pathogenic intronic
events and complicated splicing abnormalities in dystrophinopathy. Hum. Genet.
142, 59–71.
3. Fukuyama, Y., Osawa, M., and Suzuki, H. (1981). Congenital progressive muscular
dystrophy of the Fukuyama type - clinical, genetic and pathological considerations.
Brain Dev. 3, 1–29.
4. Kanagawa, M., Kobayashi, K., Tajiri, M., Manya, H., Kuga, A., Yamaguchi, Y.,
Akasaka-Manya, K., Furukawa, J.I., Mizuno, M., Kawakami, H., et al. (2016).
Identification of a Post-translational Modification with Ribitol-Phosphate and Its
Defect in Muscular Dystrophy. Cell Rep. 14, 2209–2223.
5. Muntoni, F., Brockington, M., Blake, D.J., Torelli, S., and Brown, S.C. (2002).
Defective glycosylation in muscular dystrophy. Lancet 360, 1419–1421.
6. Lim, B.C., Ki, C.S., Kim, J.W., Cho, A., Kim, M.J., Hwang, H., Kim, K.J., Hwang, Y.S.,
Park, W.Y., Lim, Y.J., et al. (2010). Fukutin mutations in congenital muscular dystrophies with defective glycosylation of dystroglycan in Korea. Neuromuscul. Disord. 20,
524–530.
7. Kobayashi, K., Kato, R., Kondo-Iida, E., Taniguchi-Ikeda, M., Osawa, M., Saito, K.,
and Toda, T. (2017). Deep-intronic variant of fukutin is the most prevalent point mutation of Fukuyama congenital muscular dystrophy in Japan. J. Hum. Genet. 62,
945–948.
8. Mount, S.M., Pettersson, I., Hinterberger, M., Karmas, A., and Steitz, J.A. (1983). The
U1 small nuclear RNA-protein complex selectively binds a 5’ splice site in vitro. Cell
33, 509–518.
9. Zamore, P.D., and Green, M.R. (1989). Identification, purification, and biochemical
characterization of U2 small nuclear ribonucleoprotein auxiliary factor. Proc. Natl.
Acad. Sci. USA 86, 9243–9247.
10. Ruskin, B., Zamore, P.D., and Green, M.R. (1988). A factor, U2AF, is required for U2
snRNP binding and splicing complex assembly. Cell 52, 207–219.
Molecular Therapy: Nucleic Acids Vol. 33 September 2023
411
Molecular Therapy: Nucleic Acids
11. Buratti, E., and Baralle, F.E. (2004). Influence of RNA secondary structure on the premRNA splicing process. Mol. Cell Biol. 24, 10505–10514.
12. Havens, M.A., and Hastings, M.L. (2016). Splice-switching antisense oligonucleotides
as therapeutic drugs. Nucleic Acids Res. 44, 6549–6563.
13. Shibata, S., Ajiro, M., and Hagiwara, M. (2020). Mechanism-Based Personalized
Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion. Cell Chem.
Biol. 27, 1472–1482.e6.
25. Corvelo, A., Hallegger, M., Smith, C.W.J., and Eyras, E. (2010). Genome-wide association between branch point properties and alternative splicing. PLoS Comput. Biol.
6, e1001016.
26. Mercer, T.R., Clark, M.B., Andersen, S.B., Brunck, M.E., Haerty, W., Crawford, J.,
Taft, R.J., Nielsen, L.K., Dinger, M.E., and Mattick, J.S. (2015). Genome-wide discovery of human splicing branchpoints. Genome Res. 25, 290–303.
14. Nishida, A., Kataoka, N., Takeshima, Y., Yagi, M., Awano, H., Ota, M., Itoh, K.,
Hagiwara, M., and Matsuo, M. (2011). Chemical treatment enhances skipping of a
mutated exon in the dystrophin gene. Nat. Commun. 2, 308.
27. Taniguchi-Ikeda, M., Kobayashi, K., Kanagawa, M., Yu, C.C., Mori, K., Oda, T., Kuga,
A., Kurahashi, H., Akman, H.O., DiMauro, S., et al. (2011). Pathogenic exon-trapping
by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 478,
127–131.
15. Sako, Y., Ninomiya, K., Okuno, Y., Toyomoto, M., Nishida, A., Koike, Y., Ohe, K., Kii,
I., Yoshida, S., Hashimoto, N., et al. (2017). Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy. Sci. Rep. 7, 46126.
28. Canson, D., Glubb, D., and Spurdle, A.B. (2020). Variant effect on splicing regulatory
elements, branchpoint usage, and pseudoexonization: Strategies to enhance bioinformatic prediction using hereditary cancer genes as exemplars. Hum. Mutat. 41,
1705–1721.
16. Boisson, B., Honda, Y., Ajiro, M., Bustamante, J., Bendavid, M., Gennery, A.R.,
Kawasaki, Y., Ichishima, J., Osawa, M., Nihira, H., et al. (2019). Rescue of recurrent
deep intronic mutation underlying cell type-dependent quantitative NEMO deficiency. J. Clin. Invest. 129, 583–597.
29. Nazari, I., Tayara, H., and Chong, K.T. (2019). Branch Point Selection in RNA
Splicing Using Deep Learning. IEEE Access 7, 1800–1807.
17. Wu, G., Fan, L., Edmonson, M.N., Shaw, T., Boggs, K., Easton, J., Rusch, M.C., Webb,
T.R., Zhang, J., and Potter, P.M. (2018). Inhibition of SF3B1 by molecules targeting
the spliceosome results in massive aberrant exon skipping. RNA 24, 1056–1066.
18. Muraki, M., Ohkawara, B., Hosoya, T., Onogi, H., Koizumi, J., Koizumi, T., Sumi, K.,
Yomoda, J.i., Murray, M.V., Kimura, H., et al. (2004). Manipulation of alternative
splicing by a newly developed inhibitor of Clks. J. Biol. Chem. 279, 24246–24254.
19. Yoshida, M., Kataoka, N., Miyauchi, K., Ohe, K., Iida, K., Yoshida, S., Nojima, T.,
Okuno, Y., Onogi, H., Usui, T., et al. (2015). Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia. Proc. Natl. Acad. Sci. USA 112,
2764–2769.
20. Kotake, Y., Sagane, K., Owa, T., Mimori-Kiyosue, Y., Shimizu, H., Uesugi, M.,
Ishihama, Y., Iwata, M., and Mizui, Y. (2007). Splicing factor SF3b as a target of
the antitumor natural product pladienolide. Nat. Chem. Biol. 3, 570–575.
21. Hasegawa, M., Miura, T., Kuzuya, K., Inoue, A., Won Ki, S., Horinouchi, S., Yoshida,
T., Kunoh, T., Koseki, K., Mino, K., et al. (2011). Identification of SAP155 as the target
of GEX1A (Herboxidiene), an antitumor natural product. ACS Chem. Biol. 6,
229–233.
22. Kaida, D., Motoyoshi, H., Tashiro, E., Nojima, T., Hagiwara, M., Ishigami, K.,
Watanabe, H., Kitahara, T., Yoshida, T., Nakajima, H., et al. (2007). Spliceostatin
A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat.
Chem. Biol. 3, 576–583.
23. Ling, Y., Alshareef, S., Butt, H., Lozano-Juste, J., Li, L., Galal, A.A., Moustafa, A.,
Momin, A.A., Tashkandi, M., Richardson, D.N., et al. (2017). Pre-mRNA splicing
repression triggers abiotic stress signaling in plants. Plant J. 89, 291–309.
24. Signal, B., Gloss, B.S., Dinger, M.E., and Mercer, T.R. (2018). Machine learning annotation of human branchpoints. Bioinformatics 34, 920–927.
412
Molecular Therapy: Nucleic Acids Vol. 33 September 2023
30. Mendell, J.R., Rodino-Klapac, L.R., Sahenk, Z., Roush, K., Bird, L., Lowes, L.P.,
Alfano, L., Gomez, A.M., Lewis, S., Kota, J., et al.; Eteplirsen Study Group (2013).
Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74,
637–647.
31. Frank, D.E., Schnell, F.J., Akana, C., El-Husayni, S.H., Desjardins, C.A., Morgan, J.,
Charleston, J.S., Sardone, V., Domingos, J., Dickson, G., et al.; SKIP-NMD Study
Group (2020). Increased dystrophin production with golodirsen in patients with
Duchenne muscular dystrophy. Neurology 94, e2270–e2282.
32. Komaki, H., Nagata, T., Saito, T., Masuda, S., Takeshita, E., Sasaki, M., Tachimori, H.,
Nakamura, H., Aoki, Y., and Takeda, S. (2018). Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with
Duchenne muscular dystrophy. Sci. Transl. Med. 10, eaan0713.
33. Wagner, K.R., Kuntz, N.L., Koenig, E., East, L., Upadhyay, S., Han, B., and Shieh, P.B.
(2021). Safety, tolerability, and pharmacokinetics of casimersen in patients with
Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve 64, 285–292.
34. Holgersen, E.M., Gandhi, S., Zhou, Y., Kim, J., Vaz, B., Bogojeski, J., Bugno, M.,
Shalev, Z., Cheung-Ong, K., Gonçalves, J., et al. (2021). Transcriptome-Wide OffTarget Effects of Steric-Blocking Oligonucleotides. Nucleic Acid Ther. 31, 392–403.
35. Watanabe, N., Nagata, T., Satou, Y., Masuda, S., Saito, T., Kitagawa, H., Komaki, H.,
Takagaki, K., and Takeda, S. (2018). NS-065/NCNP-01: An Antisense
Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne
Muscular Dystrophy. Mol. Ther. Nucleic Acids 13, 442–449.
36. Takeuchi, A., Takahashi, Y., Iida, K., Hosokawa, M., Irie, K., Ito, M., Brown, J.B.,
Ohno, K., Nakashima, K., and Hagiwara, M. (2020). Identification of Qk as a Glial
Precursor Cell Marker that Governs the Fate Specification of Neural Stem Cells to
a Glial Cell Lineage. Stem Cell Rep. 15, 883–897.
...
論文の公開元へ
